XBiotech Inc (XBIT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.15 is considered Undervalued compared with the five-year average of 19.33. The fair price of XBiotech Inc (XBIT) is between 805.54 to 806.37 according to relative valuation method. Compared to the current price of 2.32 USD , XBiotech Inc By Undervalued By 99.71%.

Relative Value

Fair Zone

805.54-806.37

Current Price：2.32

99.71%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is XBiotech Inc (XBIT) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

XBiotech Inc (XBIT) has a current Price-to-Book (P/B) ratio of 0.43. Compared to its 3-year average P/B ratio of 0.71, the current P/B ratio is approximately -38.54% higher. Relative to its 5-year average P/B ratio of 0.83, the current P/B ratio is about -47.72% higher. XBiotech Inc (XBIT) has a Forward Free Cash Flow (FCF) yield of approximately -32.86%. Compared to its 3-year average FCF yield of -18.97%, the current FCF yield is approximately 73.23% lower. Relative to its 5-year average FCF yield of -8.77%, the current FCF yield is about 274.88% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XBIT competitors is 223.99, providing a benchmark for relative valuation. XBiotech Inc Corp (XBIT.O) exhibits a P/S ratio of 0.15, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XBIT increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XBIT in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XBIT currently overvalued or undervalued?

What is XBiotech Inc (XBIT) fair value?

XBIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of XBiotech Inc (XBIT) is between 805.54 to 806.37 according to relative valuation method.

How does XBIT's valuation metrics compare to the industry average?

The average P/S ratio for XBIT's competitors is 223.99, providing a benchmark for relative valuation. XBiotech Inc Corp (XBIT) exhibits a P/S ratio of 0.15, which is -99.93% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for XBiotech Inc (XBIT) as of Mar 03 2026?

As of Mar 03 2026, XBiotech Inc (XBIT) has a P/B ratio of 0.43. This indicates that the market values XBIT at 0.43 times its book value.

What is the current FCF Yield for XBiotech Inc (XBIT) as of Mar 03 2026?

As of Mar 03 2026, XBiotech Inc (XBIT) has a FCF Yield of -32.86%. This means that for every dollar of XBiotech Inc's market capitalization, the company generates -32.86 cents in free cash flow.

What is the current Forward P/E ratio for XBiotech Inc (XBIT) as of Mar 03 2026?

As of Mar 03 2026, XBiotech Inc (XBIT) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of XBiotech Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for XBiotech Inc (XBIT) as of Mar 03 2026?

As of Mar 03 2026, XBiotech Inc (XBIT) has a Forward P/S ratio of 0.15. This means the market is valuing XBIT at $0.15 for every dollar of expected revenue over the next 12 months.

XBIT Valuation